Brown Advisory
SUPN icon

Brown Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

Brown Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-13,469
Closed -$205K – 1077
2016
Q1 		$205K Sell
13,469
-28,000
-68% -$365K ﹤0.01% 924
2015
Q4 		$557K Buy
+41,469
New +$641K ﹤0.01% 670

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory's SUPN Position: Q2 2016 in Review

Brown Advisory sold out of Supernus Pharmaceuticals (SUPN) in Q2 2016, closing a stake of 13,469 shares — an estimated $205K sold.

Brown Advisory first reported a position in SUPN in Q4 2015 and held it in 2 quarters. The position peaked at $557K in Q4 2015. 214 funds tracked by Wall St. Rank hold SUPN as of Q2 2016.

  • Brown Advisory reported no remaining Supernus Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Brown Advisory sold 13,469 Supernus Pharmaceuticals shares in Q2 2016, an estimated $205K.
  • Brown Advisory first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Brown Advisory's Supernus Pharmaceuticals position peaked at $557K in Q4 2015.
  • 214 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2016.

Based on Brown Advisory's 13F filing for Q2 2016, filed 9 Aug 2016.